Insider tied to Abeona (ABEO) files to sell 18,666 shares via Rule 144

Rhea-AI Filing Summary

Abeona Therapeutics investor plans small stock sale under Rule 144. A notice was filed to potentially sell 18,666 shares of Abeona Therapeutics common stock through broker Stifel Nicolaus & Company on or after 01/22/2026 on the Nasdaq market. The aggregate market value of the proposed sale is listed as $99,507.00.

The shares relate to equity compensation. The filer acquired 48,169 shares of common stock on 01/21/2026 through restricted stock units granted by the issuer, with “equity compensation” described as the form of payment. The filing also notes that 51,191,361 shares of Abeona common stock were outstanding, providing context for the size of the planned sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	18666	99507.00	51191361	01/22/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/21/2026	Restricted Stock Units	Issuer			48169	01/21/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Abeona Therapeutics (ABEO) disclose in this Form 144?

The notice states that a holder of Abeona Therapeutics common stock may sell 18,666 shares under Rule 144 through broker Stifel Nicolaus & Company on or after 01/22/2026 on the Nasdaq, with an aggregate market value of $99,507.00.

How many Abeona Therapeutics (ABEO) shares are proposed to be sold and what is their value?

The filer indicates an intent to sell 18,666 shares of Abeona common stock with an aggregate market value of $99,507.00, to be transacted on the Nasdaq.

How were the Abeona Therapeutics (ABEO) shares being sold under Form 144 acquired?

The filing explains that 48,169 shares of Abeona common stock were acquired on 01/21/2026 via restricted stock units from the issuer, with the nature of payment listed as equity compensation.

What is the total number of Abeona Therapeutics (ABEO) shares outstanding referenced in the Form 144?

The Form 144 states that there were 51,191,361 shares of Abeona Therapeutics common stock outstanding, which serves as a baseline figure relative to the 18,666 shares proposed for sale.

Which broker is handling the proposed Abeona Therapeutics (ABEO) Rule 144 sale?

The planned Rule 144 sale of Abeona Therapeutics common stock is listed as being handled by Stifel Nicolaus & Company Inc, located at 501 N Broadway, St. Louis, MO 63102.

On which exchange are the Abeona Therapeutics (ABEO) shares expected to be sold under this Form 144?

The Form 144 indicates that the 18,666 Abeona Therapeutics common shares are expected to be sold on the Nasdaq securities exchange.